Clinical Characteristics of Primary Liver Cancer

Status Recruiting

Clinical Trial Summary

Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC.

Clinical Trial Description

Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. PLC mainly includes hepatocellular carcinoma (75%-85%) and intrahepatic cholangiocarcinoma (10%-15%). In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. Common risk factors for PLC include Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection, alcohol consumption, metabolic factors, etc. Although antiviral drugs can control or even cure chronic HBV and HCV to a certain extent, chronic viral infection is still the leading cause of PLC worldwide. In addition, with the prevalence of obesity, diabetes and non-alcoholic fatty liver disease (NAFLD), the incidence of non-infectious PLC is gradually increasing. In recent years, NAFLD has gradually become the leading cause of liver transplant waiting list for patients with hepatocellular carcinoma in the United States. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC. Currently, there are few large, single-center cohort studies on the clinical features and long-term prognosis of PLC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06325267
Study type	Observational
Source	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact	Jie Li, M.D.,Ph.D
Phone	15863787910
Email	lijier@nju.edu.cn
Status	Recruiting
Phase
Start date	January 1, 2010
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03161925` - Chinese Liver Cancer Clinical Survey	N/A
Completed	`NCT00261378` - Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation	Phase 2
Enrolling by invitation	`NCT05609448` - MRI-guided Holmium-166 Radioembolization	N/A
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Not yet recruiting	`NCT05353894` - Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers	Phase 1
Completed	`NCT03518632` - Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)	N/A
Terminated	`NCT00003530` - Antineoplaston Therapy in Treating Patients With Primary Liver Cancer	Phase 2
Recruiting	`NCT04806464` - Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer	Phase 1
Recruiting	`NCT06342414` - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Completed	`NCT01116804` - Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)	Phase 1
Recruiting	`NCT03067493` - RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial	Phase 2
Completed	`NCT05183776` - Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT	N/A
Not yet recruiting	`NCT06430983` - Recurrent Liver Cancer: Reconceptualization and Reevaluation
Recruiting	`NCT05677724` - Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment
Not yet recruiting	`NCT03178929` - Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma	N/A
Recruiting	`NCT05267080` - Registry on Percutaneous Electrochemotherapy
Not yet recruiting	`NCT02327819` - The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer	N/A
Completed	`NCT01640522` - Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms	N/A
Completed	`NCT00408122` - Evaluation of Preoperative Investigations in Patients With Liver Cancer	N/A
Recruiting	`NCT03297255` - Primary Liver Cancer Cohort of South China	N/A